VivoSeq
Metabolic & Endocrine

Diabetes Mellitus, Type 1

9

Pipeline Programs↗

8

Active Trials↗

6

Companies Involved↗

Diabetes Mellitus, Type 1 is an early-stage landscape with 9 programs across 6 companies. The most active players are Bristol-Myers Squibb, Pfizer, Novo Nordisk. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

22/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

3 programs

Phase 3Eli Lilly logo

Eli Lilly

2 programs

Phase 3Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

1 program

Phase 3T

Tandem Diabetes Care, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

12

clinical trials

Recruiting5 · 42%
Completed4 · 33%
Active, not recruiting3 · 25%

Clinical Trials

Trial Activity

12 trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07222137·150 enrolled
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07222332·300 enrolled
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 3·NCT04786262·52 enrolled
A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan
Recruiting·Novo Nordisk logoNovo Nordisk·N/A·NCT06807190·630 enrolled
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT07076199·877 enrolled
A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes
Active, not recruiting·Novo Nordisk logoNovo Nordisk·N/A·NCT07160816·245 enrolled
NIDDK Share Plus: Continuous Glucose Monitoring With Data Sharing in Older Adults With T1D and Their Care Partners
Active, not recruiting·UUniversity of Utah·Preclinical·NCT05937321·168 enrolled
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT05180591·150 enrolled
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
Completed·SStanford University·Phase 1·NCT07090824·10 enrolled
A Family-Based Approach to Treat Obesity and Its Co-morbidities in Youth With Type 1 Diabetes (T1D) and Their Parents
Completed·SState University of New York at Buffalo·Preclinical·NCT05756361·22 enrolled
A Control-IQ Technology 2.0 Feasibility Study in Adult and Adolescent Subjects
Completed·TTandem Diabetes Care, Inc.·Preclinical·NCT05014789·66 enrolled
The Impact of Daily CarboHydrate Intake on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-loop System (Medtronic MiniMed 780G): a Multi-center Real-world Observational Study
Completed·UUniversity of Ljubljana, Faculty of Medicine·N/A·NCT05866900·347 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)